GO:0098691 dopaminergic synapse: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098691 (dopaminergic synapse) is a cellular component term defined as a synapse that uses dopamine as a neurotransmitter.
• Dopaminergic synapses are specialized junctions where dopamine is released, received, and cleared, and they are central to motor control, reward, and cognition.
• The presynaptic terminal, postsynaptic density, and surrounding glia form a tripartite synapse that regulates dopamine signaling.
• Dopaminergic synapse dysfunction is linked to Parkinson's disease, schizophrenia, and addiction-related disorders.
• Key proteins include tyrosine hydroxylase, dopamine transporters, dopamine receptors, and alpha-synuclein, which modulate synaptic content and tone.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of dopaminergic synapse genes.
Description
The dopaminergic synapse (GO:0098691) is a cellular component defined as a synapse that uses dopamine as a neurotransmitter. It is the principal site of dopamine release, reception, and signal termination in the nervous system, and it is essential for motor control, reward processing, and cognitive function. Because dopamine signaling is implicated in major neurological and psychiatric disorders, the dopaminergic synapse is a focal point for both basic and translational neuroscience. Researchers study this structure to understand how presynaptic release, postsynaptic receptor activation, and glial modulation are coordinated. Molecular imaging studies in humans and small laboratory animals have provided in vivo evidence of dopaminergic synapse function and its alterations in disease. The term GO:0098691 therefore captures a discrete anatomical and functional entity that can be interrogated with genetic, pharmacological, and imaging tools.
dopaminergic synapse At A Glance
| GO ID | GO:0098691 |
|---|---|
| GO term | dopaminergic synapse |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Synaptic transmission using dopamine as the neurotransmitter |
| Definition | A synapse that uses dopamine as a neurotransmitter. |
| Related disease | Parkinson's disease, schizophrenia, addiction |
| Key proteins | Tyrosine hydroxylase, dopamine transporter, dopamine receptors, alpha-synuclein |
What Is GO:0098691?
GO:0098691 (dopaminergic synapse) is a cellular component ontology term that describes a synapse in which dopamine serves as the neurotransmitter. This definition encompasses the presynaptic terminal that releases dopamine, the postsynaptic specialization that responds to dopamine, and the associated glial elements that modulate the synaptic environment. The term is used to annotate gene products that localize to or function specifically at these dopaminergic junctions, distinguishing them from other synapse types that use different neurotransmitters.
Why Is dopaminergic synapse Important in Cell Biology?
The dopaminergic synapse is a critical node in neural circuits that govern movement, motivation, and reward, and its dysfunction is a hallmark of several high-impact disorders. Parkinson's disease involves degeneration of nigrostriatal dopaminergic synapses, leading to motor deficits that can be partially restored by neurotransplantation strategies. Alpha-synuclein, a protein strongly linked to Parkinson's disease, modulates dopaminergic synaptic content and tone, directly tying synaptic biology to disease pathogenesis. In addition, dopaminergic synapses in the olfactory bulb are subject to hormonal regulation, such as by estradiol, indicating broader roles in sensory processing and plasticity. Understanding the molecular composition and regulation of this synapse is therefore essential for developing targeted therapies and for interpreting in vivo imaging signals.
• Dopaminergic synapses are the primary sites of dopamine neurotransmission in the brain.
• They are central to motor control, as evidenced by nigrostriatal synapse degeneration in Parkinson's disease.
• They mediate reward and reinforcement, contributing to addiction and mood disorders.
• Alpha-synuclein modulates dopaminergic synaptic content and tone, linking synaptic dysfunction to Parkinson's disease.
• Dopaminergic synapses in the olfactory bulb are regulated by estradiol, affecting sensory processing.
• Calcium channel-mediated dopaminergic modulation occurs in subthalamonigral synapses, influencing circuit excitability.
• Projection-specific signals establish functionally segregated dopaminergic synapses, enabling precise circuit wiring.
• Molecular imaging of dopaminergic synapses in humans and animals provides biomarkers for disease progression.
• Tripartite synapse interactions with glia add another layer of regulation to dopamine signaling.
• CRISPR-based genetic models allow causal testing of dopaminergic synapse gene function.
Structure and Composition of dopaminergic synapse
Presynaptic terminal and dopamine release machinery
In simple terms: The sending side of the synapse packages dopamine and releases it on demand.
The presynaptic terminal of a dopaminergic synapse contains the machinery for dopamine synthesis, storage, and release. Tyrosine hydroxylase converts tyrosine to L-DOPA, which is then decarboxylated to dopamine and packaged into synaptic vesicles. Upon stimulation, vesicles fuse with the plasma membrane to release dopamine into the synaptic cleft. This process is modulated by calcium channels, as shown in the subthalamonigral synapse where differential calcium channel-mediated dopaminergic modulation occurs. The presynaptic terminal is also a site of action for alpha-synuclein, which can influence synaptic content and tone.
Postsynaptic specialization and dopamine receptors
In simple terms: The receiving side of the synapse detects dopamine and passes the signal forward.
The postsynaptic specialization of a dopaminergic synapse is enriched in dopamine receptors (D1-like and D2-like) that bind dopamine and initiate downstream signaling cascades. These receptors are coupled to G proteins and can modulate ion channels and second messengers. The postsynaptic density also contains scaffolding proteins that anchor receptors and signaling molecules. Projection-specific signals establish functionally segregated dopaminergic synapses, meaning that the postsynaptic composition can vary depending on the circuit. This specialization ensures that dopamine release translates into appropriate changes in postsynaptic excitability.
Tripartite synapse and glial modulation
In simple terms: Support cells around the synapse also help control dopamine signals.
The concept of the tripartite synapse includes presynaptic and postsynaptic elements plus surrounding glial cells, particularly astrocytes. In dopaminergic synapses, glia can take up dopamine, release gliotransmitters, and modulate synaptic strength. Verharen et al. (2020) highlighted dopaminergic control over the tripartite synapse, emphasizing that glial cells are active participants in dopamine signaling. This adds a layer of complexity to the synapse, as glial dysfunction could contribute to dopaminergic disorders.
Dopamine clearance and reuptake
In simple terms: After dopamine sends its signal, it must be removed to reset the synapse.
Dopamine clearance from the synaptic cleft is primarily mediated by the dopamine transporter (DAT) located on the presynaptic membrane. DAT reuptakes dopamine into the presynaptic terminal, terminating the signal and allowing for recycling. This process is critical for maintaining synaptic homeostasis, and its dysregulation is implicated in disorders such as Parkinson's disease and addiction. Alpha-synuclein can also affect dopamine content and tone, potentially by influencing transporter function or vesicle dynamics.
Hormonal and developmental regulation of synapse formation
In simple terms: Hormones and developmental cues shape where and when these synapses form.
Dopaminergic synapse formation is not static; it is influenced by hormonal and developmental signals. For example, estradiol affects dopaminergic synapse formation in the mouse olfactory bulb, demonstrating that steroid hormones can regulate synaptic connectivity in specific regions. Projection-specific signals also guide the establishment of functionally segregated dopaminergic synapses during development. These findings indicate that the dopaminergic synapse is a dynamic structure subject to both intrinsic genetic programs and extrinsic modulation.
Key Genes Involved in GO:0098691 dopaminergic synapse
The following genes and proteins are central to the structure, function, and regulation of the dopaminergic synapse (GO:0098691).
| Gene | Major Role | Research Relevance |
|---|---|---|
| TH | Tyrosine hydroxylase, rate-limiting enzyme in dopamine synthesis | Target for Parkinson's disease models and dopamine depletion studies |
| SLC6A3 | Dopamine transporter (DAT), clears dopamine from synapse | Key marker of dopaminergic terminals; knockout models show altered dopamine dynamics |
| DRD1 | Dopamine receptor D1, postsynaptic excitatory signaling | Implicated in reward, addiction, and motor control |
| DRD2 | Dopamine receptor D2, postsynaptic inhibitory signaling | Target of antipsychotics; linked to schizophrenia and Parkinson's disease |
| SNCA | Alpha-synuclein, modulates synaptic content and tone | Central to Parkinson's disease pathogenesis; modulates dopamine release |
| DDC | DOPA decarboxylase, converts L-DOPA to dopamine | Enzyme in dopamine synthesis pathway |
| DBH | Dopamine beta-hydroxylase, converts dopamine to norepinephrine | Distinguishes noradrenergic from dopaminergic neurons |
| SLC18A2 | Vesicular monoamine transporter 2 (VMAT2), packages dopamine into vesicles | Essential for dopamine storage; target for imaging |
| MAOA | Monoamine oxidase A, degrades dopamine | Regulates dopamine levels; inhibitor targets in depression |
| MAOB | Monoamine oxidase B, degrades dopamine | Inhibitor target in Parkinson's disease |
| COMT | Catechol-O-methyltransferase, degrades dopamine | Influences dopamine availability; genetic variants affect cognition |
| CACNA1A | Calcium channel subunit, mediates dopamine release | Modulates dopaminergic transmission in subthalamonigral synapse |
| CACNA1B | Calcium channel subunit, mediates dopamine release | Involved in presynaptic dopamine release |
| GRIN1 | NMDA receptor subunit, postsynaptic modulation | Integrates dopamine and glutamate signaling |
| GRIA1 | AMPA receptor subunit, postsynaptic modulation | Mediates fast excitatory transmission at dopaminergic synapses |
| GAD1 | Glutamic acid decarboxylase, GABA synthesis | Involved in local circuit interactions with dopaminergic synapses |
| GFAP | Glial fibrillary acidic protein, astrocyte marker | Tripartite synapse component; modulates dopamine |
| BDNF | Brain-derived neurotrophic factor, synaptic plasticity | Regulates dopaminergic synapse development and function |
How Is dopaminergic synapse Regulated?
Dopaminergic synapse function is regulated at multiple levels, including presynaptic release probability, postsynaptic receptor sensitivity, and glial modulation. Calcium channel activity directly controls dopamine release, as shown in the subthalamonigral synapse where differential calcium channel-mediated dopaminergic modulation occurs. Hormonal signals such as estradiol can regulate synapse formation in specific regions like the olfactory bulb. Projection-specific signals establish functionally segregated dopaminergic synapses, indicating that intrinsic genetic programs and extrinsic cues cooperate to shape synaptic properties. Additionally, alpha-synuclein modulates dopaminergic synaptic content and tone, providing a regulatory link between synaptic proteins and disease.
dopaminergic synapse and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SNCA | Parkinson's disease; alpha-synuclein modulates dopamine synaptic content | Knockout or point-mutation (A53T) knock-in mice; overexpression models |
| SLC6A3 | Dopamine transporter dysfunction; altered dopamine clearance | DAT knockout mice; knock-in of human variants |
| DRD2 | Schizophrenia; antipsychotic target | D2 receptor knockout or overexpression models |
| TH | Dopa-responsive dystonia; Parkinson's disease | TH knockout or conditional knockout mice |
| CACNA1A | Episodic ataxia; dopaminergic modulation | Point-mutation knock-in mice; calcium channel subunit knockout |
Parkinson's disease and nigrostriatal degeneration
Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to degeneration of nigrostriatal dopaminergic synapses. This results in motor symptoms such as tremor, rigidity, and bradykinesia. Tsui et al. (2011) reviewed the functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation as a therapeutic strategy, highlighting the central role of this synapse in disease pathology. Alpha-synuclein, a key protein in Parkinson's disease, modulates dopaminergic synaptic content and tone, further linking synaptic dysfunction to neurodegeneration.
Schizophrenia and dopaminergic dysfunction
Schizophrenia has been associated with altered dopaminergic neurotransmission, particularly in mesolimbic and mesocortical pathways. While the exact mechanisms remain under investigation, molecular imaging studies in humans have provided evidence of dopaminergic synapse alterations in patients. The tripartite synapse, including glial modulation, may also contribute to the pathophysiology of schizophrenia. Understanding the dopaminergic synapse at a molecular level is therefore critical for developing better treatments.
Addiction and reward circuitry
Dopaminergic synapses in the reward circuitry, such as those in the nucleus accumbens and ventral tegmental area, are central to addiction. Drugs of abuse can hijack dopamine signaling, leading to persistent synaptic changes. The tripartite synapse concept highlights how glial cells and other modulators influence dopamine signaling in addiction. Projection-specific signals that establish functionally segregated dopaminergic synapses may explain why different circuits are differentially vulnerable to addictive substances.
Olfactory and sensory processing disorders
Dopaminergic synapses are present in the olfactory bulb, where they contribute to sensory processing. Estradiol has been shown to affect dopaminergic synapse formation in the mouse olfactory bulb, suggesting that hormonal fluctuations could influence olfactory function. Disruptions in dopaminergic signaling in the olfactory bulb have been linked to anosmia in neurodegenerative diseases such as Parkinson's disease, where olfactory deficits often precede motor symptoms.
From dopaminergic synapse-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate dopamine release? | Knockout of gene X in dopaminergic neurons; measure evoked dopamine release |
| Does a disease-associated point mutation alter synaptic function? | Point-mutation knock-in of the variant; compare to wild-type |
| Where is protein X localized in the dopaminergic synapse? | Tagged knock-in (e.g., GFP) for imaging; co-localization with synaptic markers |
| Does overexpression of gene Y mimic disease phenotype? | Overexpression of gene Y in dopaminergic neurons; assess synaptic and behavioral changes |
| What is the role of glial gene Z in dopamine signaling? | Conditional knockout of gene Z in astrocytes; tripartite synapse assays |
| How does hormonal regulation affect synapse formation? | Estradiol treatment in knockout or wild-type mice; quantify synapse numbers |
How to Study the dopaminergic synapse Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PET/SPECT imaging | Dopamine transporter/receptor availability | In vivo assessment of dopaminergic synapse integrity in humans |
| Fast-scan cyclic voltammetry | Real-time dopamine release and reuptake | Measuring evoked dopamine dynamics in brain slices |
| Patch-clamp electrophysiology | Postsynaptic currents and excitability | Characterizing receptor function at dopaminergic synapses |
| Immunohistochemistry | Synaptic protein localization | Visualizing dopaminergic terminals and receptors |
| CRISPR knockout | Gene function loss | Testing causal role of candidate genes in dopamine transmission |
| Knock-in reporter | Protein localization and dynamics | Tracking synaptic proteins in live cells |
| RNA-seq | Transcriptional changes | Identifying gene expression changes in disease models |
| Proteomics | Protein abundance and modifications | Discovering synaptic protein networks |
Molecular imaging of dopaminergic synapses in vivo
Molecular imaging techniques such as PET and SPECT allow non-invasive assessment of dopaminergic synapse integrity in humans and small laboratory animals. Nikolaus et al. (2007) reviewed molecular imaging studies in humans and in small laboratory animals, demonstrating that radioligands targeting dopamine transporters, receptors, and synthesis enzymes can quantify synaptic density and function. These methods are valuable for tracking disease progression and evaluating therapeutic interventions.
Electrophysiology and amperometry
Electrophysiological recordings and amperometry can measure dopamine release and postsynaptic responses at dopaminergic synapses. For example, differential calcium channel-mediated dopaminergic modulation in the subthalamonigral synapse was characterized using electrophysiological approaches. These techniques provide high temporal resolution of synaptic events and can be combined with genetic manipulations to dissect molecular mechanisms.
Genetic and CRISPR-based models
CRISPR/Cas9 genome editing enables the creation of knockout, point-mutation, knock-in, and overexpression models to study dopaminergic synapse genes. Projection-specific signals that establish functionally segregated dopaminergic synapses have been investigated using genetic mouse models. Estradiol effects on dopaminergic synapse formation in the olfactory bulb were studied using mouse genetics. These models allow causal testing of gene function in vivo.
Proteomics and transcriptomics
Mass spectrometry-based proteomics and RNA sequencing can identify the molecular composition of dopaminergic synapses. Alpha-synuclein's role in modulating dopaminergic synaptic content and tone has been explored using biochemical and proteomic approaches. These methods can reveal disease-associated changes in synaptic proteins and guide the selection of therapeutic targets.
How CRISPR Can Be Used to Study GO:0098691 dopaminergic synapse
Knockout
CRISPR knockout of genes such as SLC6A3, DRD2, or SNCA can abolish protein function and reveal their roles in dopaminergic synapse physiology. For example, knockout of the dopamine transporter leads to altered dopamine clearance and compensatory changes. These models are essential for understanding the contribution of individual genes to synaptic transmission and behavior.
Point Mutation
Point mutations can be introduced to model disease-associated variants, such as the A53T mutation in SNCA linked to Parkinson's disease. These knock-in models allow researchers to study how specific amino acid changes affect dopaminergic synapse function, protein aggregation, and neurodegeneration.
Knock-in
Knock-in of reporter tags (e.g., GFP) or human disease variants enables precise tracking of proteins in the dopaminergic synapse. Tagged knock-in models can visualize synaptic localization and dynamics, while disease-variant knock-ins provide insights into pathogenesis. Projection-specific signals that establish functionally segregated dopaminergic synapses can be studied using knock-in approaches.
Overexpression
Overexpression of genes such as SNCA or DRD2 can mimic pathological states and test whether increased protein levels are sufficient to cause synaptic dysfunction. These models are particularly useful for studying gain-of-function mechanisms and for preclinical drug testing.
How EDITGENE Supports dopaminergic synapse Research
Researchers studying dopaminergic synapse-related genes often need to determine whether a candidate gene is causally involved in synaptic function, disease pathogenesis, or treatment response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous hypothesis testing and accelerating discovery in dopaminergic synapse biology.
Contact EDITGENE today to design your custom CRISPR model for dopaminergic synapse research.
Frequently Asked Questions About dopaminergic synapse
What is GO:0098691?
GO:0098691 is the Gene Ontology term for dopaminergic synapse, a cellular component defined as a synapse that uses dopamine as a neurotransmitter.
What genes are involved in dopaminergic synapse?
Key genes include TH, SLC6A3 (DAT), DRD1, DRD2, SNCA, DDC, DBH, SLC18A2, MAOA, MAOB, COMT, and calcium channel subunits such as CACNA1A.
What diseases are associated with dopaminergic synapse dysfunction?
Parkinson's disease, schizophrenia, addiction, and olfactory disorders are linked to dopaminergic synapse dysfunction.
How can I study dopaminergic synapses in the lab?
Methods include molecular imaging (PET/SPECT), electrophysiology, amperometry, CRISPR knockout/knock-in models, and proteomics.
What is the role of alpha-synuclein at the dopaminergic synapse?
Alpha-synuclein modulates dopaminergic synaptic content and tone, and its dysfunction is linked to Parkinson's disease.
How does estradiol affect dopaminergic synapses?
Estradiol influences dopaminergic synapse formation in the mouse olfactory bulb, indicating hormonal regulation of synaptic connectivity.
What is the tripartite synapse in dopamine signaling?
The tripartite synapse includes presynaptic and postsynaptic neurons plus glial cells, which actively modulate dopamine signaling.
Can CRISPR be used to model dopaminergic synapse diseases?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can replicate disease-associated genetic changes and test their effects on synaptic function.
What imaging techniques are used for dopaminergic synapses?
PET and SPECT with radioligands targeting dopamine transporters and receptors are used in humans and small animals.
How does calcium channel activity affect dopaminergic synapses?
Calcium channels mediate dopamine release and modulate synaptic transmission, as shown in the subthalamonigral synapse.
Conclusion
The dopaminergic synapse (GO:0098691) is a fundamental cellular component that governs dopamine neurotransmission and is implicated in major neurological and psychiatric disorders. Its structure and function are shaped by a complex interplay of presynaptic, postsynaptic, and glial elements, with key roles for proteins such as tyrosine hydroxylase, dopamine transporters, receptors, and alpha-synuclein. Advances in molecular imaging, electrophysiology, and CRISPR-based genetic models continue to illuminate the mechanisms of dopaminergic synapse function and dysfunction. Targeting this synapse remains a promising avenue for therapeutic development in Parkinson's disease, schizophrenia, and addiction.
References
- 1. Verharen JPH et al.. 2020. Dopaminergic Control over the Tripartite Synapse.. Neuron 105(6):954-956 PMID: 32191856
- 2. Nikolaus S et al.. 2007. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.. Rev Neurosci 18(6):439-72 PMID: 18330212
- 3. Robles-Gómez AA et al.. 2020. Differential calcium channel-mediated dopaminergic modulation in the subthalamonigral synapse.. Synapse 74(7):e22149 PMID: 31975491
- 4. Terauchi A et al.. 2023. The projection-specific signals that establish functionally segregated dopaminergic synapses.. Cell 186(18):3845-3861.e24 PMID: 37591240
- 5. Kiyokage E et al.. 2023. Effects of estradiol on dopaminergic synapse formation in the mouse olfactory bulb.. J Comp Neurol 531(4):528-547 PMID: 36519231
- 6. Tsui A et al.. 2011. Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease.. J Neurol 258(8):1393-405 PMID: 21544566
- 7. Nikolaus S et al.. 2007. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals.. Rev Neurosci 18(6):473-504 PMID: 18330213
- 8. Sidhu A et al.. 2004. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J 18(6):637-47 PMID: 15054086
